Related Experiment Videos
Fatal pulmonary reaction from low doses of bleomycin. An idiosyncratic tissue response
Abstract:
There were two cases of fatal interstitial pneumonia secondary to bleomycin sulfate administration. Although bleomycin pulmonary toxicity is generally thought to be dose-related and occurs infrequently with a total cummulative dose less than 300 to 400 units, the two reactions reported here occurred with doses of 105 and 165 units. Fatal bleomycin-induced pneumonia has been previously reported at these low dosages, and physicians should be aware that this toxic reaction may occur as an idiosyncratic response. Previous thoracic irradiation may be a predisposing factor. Patients receiving bleomycin should be meticulously monitored by interrogation for cough, dyspnea, and chest pain; by auscultation for rales; by serial chest roentgenograms; and by determinations of vital capacity and single-breath carbon monoxide diffusing capacity.
Insights
Fatal interstitial pneumonia from bleomycin sulfate can occur at low doses, even below 400 units. Physicians should monitor patients for idiosyncratic reactions, especially those with prior thoracic irradiation.
Area of Science:
- Pulmonary Medicine
- Oncology
- Pharmacology
Background:
- Bleomycin sulfate is an antineoplastic agent used in treating various cancers.
- Pulmonary toxicity is a known, though infrequent, adverse effect of bleomycin therapy.
- The toxicity is generally considered dose-dependent, with risks increasing above cumulative doses of 300-400 units.
Observation:
- Two cases of fatal interstitial pneumonia following bleomycin sulfate administration are presented.
- These severe reactions occurred at significantly lower cumulative doses (105 and 165 units) than typically associated with toxicity.
- Previous thoracic irradiation was noted as a potential predisposing factor in these cases.
Findings:
- Fatal bleomycin-induced pneumonia can manifest as an idiosyncratic reaction, irrespective of cumulative dose.
- Low-dose bleomycin administration carries a risk of severe pulmonary toxicity.
- Idiosyncratic reactions to bleomycin may be more common than previously recognized, particularly in specific patient populations.
Implications:
- Clinicians must maintain a high index of suspicion for bleomycin pulmonary toxicity, even at low cumulative doses.
- Meticulous patient monitoring is crucial, including symptom assessment (cough, dyspnea, chest pain), physical examination (rales), and pulmonary function tests (vital capacity, diffusing capacity).
- Awareness of potential idiosyncratic responses and predisposing factors like prior thoracic irradiation is essential for patient safety during bleomycin therapy.